Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Metabolic & GLP-1/GIP Agonists

Liraglutide

Also known as: Victoza Saxenda

Evidence: Strong clinical Disclaimer: Standard FDA-approved

Mechanism & research context

GLP-1 receptor agonist with an albumin-binding fatty acid linker. FDA-approved for type 2 diabetes and obesity.

FDA-approved indication: Type 2 diabetes (Victoza); chronic weight management (Saxenda).

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Liraglutide

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00318461 PHASE3 COMPLETED

    Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Metformin Versus Metformin Monotherapy Versus Metformin and Glimepiride Combination Therapy in Subjects With Type 2 Diabetes

    Condition: Diabetes; Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT00395746 PHASE3 COMPLETED

    Effect of Liraglutide in Combination With Sulfonylurea (SU) on Glycaemic Control in Subjects With Type 2 Diabetes

    Condition: Diabetes; Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT01237119 PHASE2 COMPLETED

    48-week Phase II, Randomised, Double Blinded Placebo Controlled Multicentre Trial on Liraglutide's Safety, Efficacy and Action on Liver Histology and Metabolism in Overweight Patients With NASH +/- Type II Diabetes

    Condition: Nonalcoholic Steatohepatitis

    Sponsor: University of Birmingham

    Open on ClinicalTrials.gov ↗
  • NCT01399645 PHASE2 COMPLETED

    Randomized Trial of Liraglutide and Insulin Therapy on Hepatic Steatosis as Measured by MRI and MRS in Metformin-treated Patients With Type 2 Diabetes: an Open Pilot Study

    Condition: Nonalcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; Type 2 Diabetes

    Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

    Open on ClinicalTrials.gov ↗
  • NCT01508949 PHASE2 COMPLETED

    NNC 90-1170 Mechanism of Action: A Single-centre, Randomised, Double-blind, Parallel-group, Placebo-controlled Trial Evaluating the Effect of NNC 90-1170 on Weight and Appetite in Obese Subjects With Type 2 Diabetes

    Condition: Diabetes; Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT01511172 PHASE2 COMPLETED

    Effect on Glycemic Control of Individual Maximum Effective Dose of NNC 90-1170 as Add on Therapy to Metformin Compared to Monotherapy of NNC 90-1170 or Metformin or a Metformin-SU Combination Therapy in Patients With Type 2 Diabetes. A Double-blind, Double-dummy, Randomised, Parallel-group, Dose Titration Study With an Open Labelled OHA Arm

    Condition: Diabetes; Diabetes Mellitus, Type 2

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT01596504 PHASE2 COMPLETED

    An Open-label, Randomized, Three-parallel-group Study on Pharmacodynamic Effects of 8-week QD Treatment With Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

    Condition: Type 2 Diabetes Mellitus

    Sponsor: Sanofi

    Open on ClinicalTrials.gov ↗
  • NCT01722266 PHASE3 COMPLETED

    Liraglutide in the Treatment of Type 1 Diabetes Mellitus

    Condition: Type 1 Diabetes

    Sponsor: University at Buffalo

    Open on ClinicalTrials.gov ↗
  • NCT01847313 PHASE3 COMPLETED

    Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

    Condition: Diabetic Kidney Disease

    Sponsor: Karl Neff

    Open on ClinicalTrials.gov ↗
  • NCT01931982 PHASE4 COMPLETED

    Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2

    Condition: Type 2 Diabetes; Microvascular Dysfunction

    Sponsor: Bispebjerg Hospital

    Open on ClinicalTrials.gov ↗
  • NCT02140983 PHASE1 COMPLETED

    Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

    Condition: Insulin Resistance; Dementia

    Sponsor: Stanford University

    Open on ClinicalTrials.gov ↗
  • NCT02453711 PHASE2 COMPLETED

    Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

    Condition: Metabolism and Nutrition Disorder; Obesity

    Sponsor: Novo Nordisk A/S

    Open on ClinicalTrials.gov ↗
  • NCT02638805 PHASE3 COMPLETED

    An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide

    Condition: Diabetes Mellitus, Type 2

    Sponsor: Intarcia Therapeutics

    Open on ClinicalTrials.gov ↗
  • NCT02765399 PHASE4 COMPLETED

    The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study

    Condition: Type 2 Diabetes

    Sponsor: Helsinki University Central Hospital

    Open on ClinicalTrials.gov ↗
  • NCT02953665 PHASE2 COMPLETED

    A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease

    Condition: Parkinson Disease

    Sponsor: Cedars-Sinai Medical Center

    Open on ClinicalTrials.gov ↗
  • NCT02954627 COMPLETED

    Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects Following a Significant Weight Loss

    Condition: Osteoarthritis; Obesity

    Sponsor: Henrik Gudbergsen

    Open on ClinicalTrials.gov ↗
  • NCT04046822 PHASE4 UNKNOWN

    Could Gut Microbiome Contribute to the Therapeutic Effect of Liraglutide 3.0 mg? A Randomized Double Blind Placebo Controlled Trial

    Condition: Obesity; Weight Loss; Microbiome

    Sponsor: Federico II University

    Open on ClinicalTrials.gov ↗
  • NCT05268237 PHASE1 RECRUITING

    A Phase Ib/IIa, Single Ascending Dose Study of the Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

    Condition: Diabete Type 2

    Sponsor: Biolingus

    Open on ClinicalTrials.gov ↗
  • NCT05545800 PHASE3 UNKNOWN

    Efficacy and Safety Of Different Hypoglycemic Regimens Compared With Premixed Insulin In Patients With Type 2 Diabetes Receiving Short-term Intensive Insulin Therapy

    Condition: Type 2 Diabetes Mellitus

    Sponsor: Xiangya Hospital of Central South University

    Open on ClinicalTrials.gov ↗
  • NCT07244003 PHASE4 RECRUITING

    Efficacy and Safety of the Triple Combination Therapy of Met/SGLT-2i/GLP-1RA or Other Oral Antidiabetic Drugs in Patients With Type 2 Diabetes Exhibiting Poor Glycemic Control

    Condition: T2DM (Type 2 Diabetes Mellitus)

    Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Liraglutide yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Liraglutide, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Liraglutide. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.